Aktie FNAM EVOLUTIONARY GENOMICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Evolutionary Genomics, Inc. Other OTC

Aktien

FNAM

US30051F1012

FNAM

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Evolutionary Genomics, Inc. announced that it has received $1.004004 million in funding
EVOLUTIONARY GENOMICS, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Evolutionary Genomics, Inc. announced that it expects to receive $1.004004 million in funding
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt
Queen Mary University of London : New study pinpoints bumblebee genes that help them adapt to environmental changes
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
EVOLUTIONARY GENOMICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DZGN Aktie
  4. FNAM Aktie
  5. Nachrichten Evolutionary Genomics, Inc.
  6. Andere Sprachen